Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poseidon: Taselisib + Tamoxifen in Metastatic Breast Cancer
NCT02285179Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2014
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Tamoxifen + GDC-0032 with Tamoxifen + Placebo (2 arms). Primary endpoint: Number of patients with MTD toxicity at 4 weeks. Started Nov 2014; status: completed.
02
Drugs
taselisib / pictilisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02285179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285179.